NASDAQ:ADAP
Adaptimmune Therapeutics plc Stock News
$1.01
+0.0333 (+3.41%)
At Close: Apr 22, 2024
JonesTrading Thinks Aileron Therapeutics' Stock is Going to Recover
12:38pm, Wednesday, 08'th Apr 2020
JonesTrading analyst Soumit Roy initiated coverage with a Buy rating on Aileron Therapeutics (ALRN) today and set a price target of $5.00. The company's
JonesTrading Thinks Aileron Therapeutics’ Stock is Going to Recover
12:38pm, Wednesday, 08'th Apr 2020
JonesTrading analyst
Soumit Roy
initiated coverage with a
Buy
rating on Aileron Therapeutics (
ALRN
–
Research Report
) today and set a price target of
$5.00
. The company’s shares closed last Tue
Why Adaptimmune Therapeutics, Atreca, and CRISPR Therapeutics All Tanked In March
02:32pm, Monday, 06'th Apr 2020
These three clinical-stage biotechs are all bargains after last month's marketwide downturn.
Marshall Wace LLP Reduces Stock Holdings in Adaptimmune Therapeutics PLC - (NASDAQ:ADAP)
10:50am, Monday, 06'th Apr 2020
Marshall Wace LLP lowered its position in Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) by 63.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange C
Stocks To Watch: OPEC Goes Virtual
01:04pm, Saturday, 04'th Apr 2020
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive th
JonesTrading Thinks Monopar Therapeutics Inc's Stock is Going to Recover
12:07pm, Tuesday, 31'st Mar 2020
In a report released today, Soumit Roy from JonesTrading reiterated a Buy rating on Monopar Therapeutics Inc (MNPR). The company's shares closed last
JonesTrading Thinks Monopar Therapeutics Inc’s Stock is Going to Recover
12:07pm, Tuesday, 31'st Mar 2020
In a report released today,
Soumit Roy
from JonesTrading reiterated a
Buy
rating on Monopar Therapeutics Inc (
MNPR
–
Research Report
). The company’s shares closed last Monday at $7.09, close to
Zacks: Analysts Expect Adaptimmune Therapeutics PLC - (NASDAQ:ADAP) Will Post Quarterly Sales of $25.90 Million
08:54am, Sunday, 29'th Mar 2020
Wall Street brokerages expect Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) to report sales of $25.90 million for the current fiscal quarter, Zacks Investment Research reports. Two analysts have made
Adaptimmune Therapeutics PLC - (NASDAQ:ADAP) Short Interest Down 11.3% in March
09:16am, Saturday, 28'th Mar 2020
Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) was the recipient of a large drop in short interest during the month of March. As of March 13th, there was short interest totalling 415,600 shares, a dro
Vascular Biogenics (VBLT) Receives a Buy from JonesTrading
01:47pm, Thursday, 26'th Mar 2020
In a report released today, Soumit Roy from JonesTrading reiterated a Buy rating on Vascular Biogenics (VBLT), with a price target of $3.75. The company's
Vascular Biogenics (VBLT) Receives a Buy from JonesTrading
01:47pm, Thursday, 26'th Mar 2020
In a report released today, Soumit Roy from JonesTrading reiterated a Buy rating on Vascular Biogenics (VBLT – Research Report),
Celyad (CYAD) Received its Third Buy in a Row
08:06pm, Wednesday, 25'th Mar 2020
After H.C. Wainwright and William Blair gave Celyad (NASDAQ: CYAD) a Buy rating last month, the company received another Buy, this time from JonesTrading.
Celyad (CYAD) Received its Third Buy in a Row
08:05pm, Wednesday, 25'th Mar 2020
After H.C. Wainwright and William Blair gave Celyad (NASDAQ: CYAD) a Buy rating last month, the company received another Buy,
T2 Biosystems (TTOO) Gets a Buy Rating from JonesTrading
12:01pm, Wednesday, 25'th Mar 2020
JonesTrading analyst Soumit Roy reiterated a Buy rating on T2 Biosystems (TTOO) today and set a price target of $2.50. The company's shares closed last
T2 Biosystems (TTOO) Gets a Buy Rating from JonesTrading
12:01pm, Wednesday, 25'th Mar 2020
JonesTrading analyst Soumit Roy reiterated a Buy rating on T2 Biosystems (TTOO – Research Report) today and set a price
